We are Sorry, This Page doesn't Exist
SEC fines Mylan $30 million for Epipen disclosure failure
The Securities and Exchange Commission settled charges Friday against Mylan N.V., who agreed to pay $30 million for ac.....»»
Mylan to pay $30 million U.S. SEC fine related to EpiPen overcharge probe
Mylan NV has agreed to pay a $30 million fine to settle U.S. Securities and Exchange Commission charges it hid from investors the impact of a federal probe into the drugmaker's overbilling the government for its EpiPen allergy treatment......»»
Mylan reaches $30 million settlement in SEC"s EpiPen probe
Mylan NV has reached a tentative agreement to pay $30 million to resolve a probe by the U.S. Securities and Exchange Commission related to its emergency allergy shot EpiPen, which became the center of a firestorm over price increases......»»
Mylan deal puts future of its beleaguered EpiPen in spotlight
Mylan NV's planned merger with Pfizer Inc's off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment......»»
EpiPen maker Mylan, Pfizer's Upjohn off-patent drug business to merge
Pfizer's off-patent drug business, Upjohn, is set to merge with Mylan, maker of eme.....»»
Pfizer in talks to transition EpiPen maker into generics spinoff: spokeswoman
Pfizer Inc is in talks to merge its contract manufacturer that produces Mylan's EpiPen emergency allergy treatment into the new generics business it is creating by combining its older off-patent medicines unit with Mylan NV , a Pfizer spokeswoman said......»»
Pfizer and Mylan form a $20-billion-a-year powerhouse
One company makes Xanax and Viagra. The other makes the popular EpiPen drug for people with allergies. Now they are merging......»»
Mylan to combine with Pfizer"s off-patent medicines unit
Pfizer Inc will separate its off-patent drugs business and merge it with Mylan , the two companies confirmed on Monday, bringing blockbuster treatments Viagra, EpiPen and Lipitor under one umbrella......»»
Mylan: The EpiPen Shortage Could Sting
Mylan: The EpiPen Shortage Could Sting.....»»
Mylan: The Epipen Shortage Could Sting
Mylan: The Epipen Shortage Could Sting.....»»
Earnings Outlook: Mylan reports first-quarter earnings on Tuesday. Here’s what to expect
EpiPen maker Mylan N.V. is set to report first-quarter earnings on Tuesday morning before the market opens......»»
Mylan (MYL) to Report Q1 Earnings: What"s in the Offing?
Investors are exepcted to focus on the performance of EpiPen, newly launched drugs and the progress of the company's biosimilars pipeline when Mylan (MYL) reports results for the Q1. Mylan .....»»
FDA adds Mylan"s EpiPen to shortage list
The move by U.S. regulators to add EpiPen to the drug shortage list came on the same day Mylan's quarterly revenue disappointed Wall Street. Fred Katayama reports......»»
FDA adds Mylan's EpiPen to shortage list
The move by U.S. regulators to add EpiPen to the drug shortage list came on the same day Mylan's quarterly revenue disappointed Wall Street. Fred Katayama reports. .....»»
Mylan critic Blumenthal asks FDA to help end EpiPen shortage, Bloomberg reports
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
After a year-long search, Adamis has a partner to market its EpiPen competitor
Shares of biotech Adamis Pharmaceuticals Corp. soared more than 35% Monday, after the company said its search for a commercial partner for its competitor to Mylan N.V.’s EpiPen allergic reaction treatment is over......»»
Adamis soars 40% as its EpiPen competitor inches closer to release
Shares of biotech Adamis Pharmaceuticals Corp. soared more than 35% Monday, after the company said its search for a commercial partner for its competitor to Mylan N.V.’s EpiPen allergic reaction treatment is over......»»
Adamis has a partner to market its EpiPen competitor after a year-long search
Shares of biotech Adamis Pharmaceuticals Corp. soared more than 35% Monday, after the company said its search for a commercial partner for its competitor to Mylan N.V.’s EpiPen allergic reaction treatment is over......»»
EpiPen up for sale? Pharmaceutical maker Mylan considering 'alternatives'
The maker of the EpiPen device is considering a significant shift that could ultimately lead to a sale of the company or certain assets. Pharmaceutical giant Mylan .....»»
Mylan stock drops 3% after wipeout of a second quarter
Chief Executive Heather Bresch, who became the poster child for pharmaceutical villainy over EpiPen price hikes in 2016, also critiqued the U.S. drug pricing system......»»